Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

NVO’s underwhelming data readout also stands to benefit Amgen AMGN, which is developing its weight-loss candidate, MariTide, in a mid-stage study. Unlike CagriSema, which delivered 22.7% weight ...

Novo shares, which fell sharply on the cagrisema news, rose as much as 11% in before settling into an 8% gain midday Friday.

06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...

(This story has been corrected to say that the trial is to test long-term efficacy, not the late-stage CagriSema trial planned after data in December, in headline and paragraphs 1and 2) Sign up here.

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated comp ...

Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...

The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...

"The CagriSema [...] data in obesity was undoubtedly disappointing but it is still a higher efficacy treatment that could still show differentiation in type-2 diabetes [...]," the analysts wrote.